Concert’s CTP-543 Receives the US FDA’s Breakthrough Therapy Designation to Treat Alopecia Areata

 Concert’s CTP-543 Receives the US FDA’s Breakthrough Therapy Designation to Treat Alopecia Areata

Concert’s CTP-543 Receives the US FDA’s Breakthrough Therapy Designation to Treat Alopecia Areata

Shots:

  • The BTD is based on a P-II study assessing CTP-543 (4/8/12mg, bid) vs PBO in 149 patients with moderate-to-severe alopecia areata
  • Results: 8 & 12mg doses of CTP-543 met its 1EPs with differences in the percentage of patients achieving a ≥ 50% relative change from baseline @24wks. as measured by SALT. Therapy was well-tolerated and showed significant hair regrowth
  • CTP-543 is a JAK1 & JAK2 inhibitor and has received the US FDA’s FTD for AA. The company plans to initiate a P-III study in Q4’20

Click here ­to­ read full press release/ article | Ref: Businessswire | Image: Twitter

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post